SCYNEXIS, Inc.

SCYNEXIS, Inc. reported a net loss of $8.6 million for FY 2025, a significant improvement from a $21.3 million net loss in FY 2024. Total revenue increased substantially to $20.6 million, driven by a $19.2 million cumulative catch-up of license agreement revenue from the GSK Binding 2025 MOU and $1.4 million in product revenue. Operating loss narrowed to $16.1 million from $37.1 million, as total operating expenses decreased to $36.7 million from $40.9 million. The company ended the year with $59.0 million in total assets, $49.4 million in stockholders' equity, and cash, cash equivalents, and investments of $56.3 million. Management believes current resources are sufficient to fund operations for at least the next 12 months.

Key Takeaways